Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.55 |
| ▸ | FEN1 | P39748 | 1/20 | 0.55 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8534650 | 1.00 | SMN1; SMN2 (0.72) | SMN1; SMN2LMNAFFAR1CYP1A2RAB9A | |
| SCHEMBL8534233 | 0.88 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAFFAR1CYP1A2RAB9A | |
| SCHEMBL822901 | 0.88 | NR4A2 (0.68) | SMN1; SMN2LMNAFFAR1CYP1A2RAB9A | |
| SCHEMBL11686001 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAFFAR1CYP1A2RAB9A | |
| Fenbufen SCHEMBL11329267 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAFFAR1CYP1A2RAB9A | |
| Fenbufen SCHEMBL25117 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAFFAR1CYP1A2RAB9A | |
| Levulinic Acid SCHEMBL4826758 | 0.82 | NR4A2 (0.80) | SMN1; SMN2LMNAFFAR1CYP1A2RAB9A | |
| SCHEMBL3733726 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAFFAR1CYP1A2RAB9A | |
| Fenbufen SCHEMBL11393779 | 0.82 | SMN1; SMN2 (0.96) | SMN1; SMN2LMNAFFAR1CYP1A2RAB9A | |
| SCHEMBL800972 | 0.82 | ERCC5 (0.67) | SMN1; SMN2LMNAFFAR1CYP1A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152205-A1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-19 | — | — | US | disclosed |
| WO-2016122160-A1 | NOVEL DIOXIMESTER COMPOUND, AND PHOTOPOLYMERIZATION INITIATOR AND PHOTORESIST COMPOSITION CONTAINING SAME | 주식회사 삼양사 | 2016-08-04 | — | — | WO | disclosed |
| EP-2261236-B1 | Composition for proteasome inhibition | ONYX THERAPEUTICS INC (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO - UNESP (BR) | 2014-02-27 | — | — | US | disclosed |
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO - UNESP (BR) | 2014-02-27 | — | — | US | disclosed |
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8569335-B2 | Compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these | EMS S.A. (BR) | 2013-10-29 | — | — | US | disclosed |
| US-8569335-B2 | Compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these | EMS S.A. (BR) | 2013-10-29 | — | — | US | disclosed |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2260835-A2 | Composition for proteasome inhibition | Proteolix, Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-7741364-B2 | Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate | ABBOTT LABORATORIES (US) | 2010-06-22 | — | — | US | disclosed |
| WO-2009124371-A2 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S. A. (BR) | 2009-10-15 | — | — | WO | disclosed |
| EP-2041085-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2009-03-19 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2008002974-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-0885869-A1 | THERAPEUTIC AGENT FOR DIABETES | Japan Tobacco Inc. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | PYCR1, PPOX, DHPS | SMN1; SMN2 2315/4885LMNA 3511/4885FFAR1 4752/4885 |
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | TPMT, UTS2R, NSUN3 | SMN1; SMN2 1046/4885LMNA 3909/4885FFAR1 1465/4885 |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, CTSA, ALG1 | SMN1; SMN2 3010/4885LMNA 970/4885FFAR1 3581/4885 |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | SMN1; SMN2 2670/4885LMNA 2603/4885FFAR1 4083/4885 |
| US-20220152205-A1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | C3AR1, CFH, CSF3R | SMN1; SMN2 3424/4885LMNA 2853/4885FFAR1 1020/4885 |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | SMN1; SMN2 2923/4885LMNA 3012/4885FFAR1 4301/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | SMN1; SMN2 2923/4885LMNA 3012/4885FFAR1 4301/4885 |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | PYCR1, PPOX, DHPS | SMN1; SMN2 2315/4885LMNA 3511/4885FFAR1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.